Skip to Content


In the US, Rituxan (rituximab systemic) is a member of the following drug classes: antirheumatics, CD20 monoclonal antibodies and is used to treat Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Microscopic polyangiitis, Non-Hodgkin's Lymphoma, Pemphigus Vulgaris, Rheumatoid Arthritis and Wegener's Granulomatosis.

US matches:

Ingredient matches for Rituxan


Rituximab is reported as an ingredient of Rituxan in the following countries:

  • Canada
  • Japan
  • United States

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.